Best of ASCO® Vancouver 2024: Gynecological Cancer – Dr. Yvette Drew
OR
Co-Chairs
Dr. Sharlene Gill
Dr. Nancy Nixon
Speakers
Dr. Yvette Drew
Studies/trials discussed:
- Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
- Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
- Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
- RAMP 201: A study of Defactinib and Avutometinib in recurrent low grade serous ovarian cancer
- Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
- Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer
- Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study
- Ajuvant Chemotherapy following Concurrent Chemoradiation (CRT) in High Risk Early Stage Cervical Carcinoma Patients Following Radocal Hysterectomy : Results of NRG Oncology/ RTOG 0724/ G0G-0724
- A phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation
- versus standard chemoradiation alone in patients with locally advanced cervical cancer (INTERLACE)
- Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
- Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274).
- Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas.
